Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Autolus Therapeutics Plc ADR (AUTL)

Autolus Therapeutics Plc ADR (AUTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 612,016
  • Shares Outstanding, K 266,094
  • Annual Sales, $ 1,700 K
  • Annual Income, $ -208,380 K
  • EBIT $ -186 M
  • EBITDA $ -180 M
  • 60-Month Beta 1.98
  • Price/Sales 352.60
  • Price/Cash Flow N/A
  • Price/Book 1.22

Options Overview Details

View History
  • Implied Volatility 255.20% ( +61.42%)
  • Historical Volatility 61.88%
  • IV Percentile 93%
  • IV Rank 38.81%
  • IV High 635.73% on 12/23/24
  • IV Low 13.86% on 09/12/24
  • Put/Call Vol Ratio 1.00
  • Today's Volume 140
  • Volume Avg (30-Day) 435
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 6,639
  • Open Int (30-Day) 10,124

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.21
  • Number of Estimates 4
  • High Estimate -0.05
  • Low Estimate -0.33
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +52.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.07 +11.11%
on 12/24/24
3.45 -33.33%
on 12/02/24
-0.80 (-25.69%)
since 11/26/24
3-Month
2.07 +11.11%
on 12/24/24
5.00 -54.00%
on 10/18/24
-1.18 (-33.91%)
since 09/26/24
52-Week
2.07 +11.11%
on 12/24/24
7.45 -69.13%
on 01/12/24
-4.24 (-64.83%)
since 12/26/23

Most Recent Stories

More News
The Immunotherapy Boom: What It Means for the Future of Cancer Treatment

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Immunotherapy is revolutionizing oncology by harnessing the power of the immune system to fight cancer...

ONCY : 1.0009 (+3.19%)
AUTL : 2.30 (+2.22%)
IOVA : 7.60 (+1.47%)
ABBV : 179.20 (-0.44%)
ONC.TO : 1.41 (+9.30%)
IBRX : 2.69 (+2.28%)
Autolus Therapeutics Presents Key Findings on obe-cel at the 2024 ASH Annual Meeting

Autolus Therapeutics presents data at ASH 2024 on obe-cel for adult relapsed/refractory B-ALL, highlighting clinical outcomes and cost efficiency.Quiver AI SummaryAutolus Therapeutics plc announced its...

AUTL : 2.30 (+2.22%)
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

AUTL : 2.30 (+2.22%)
Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

AUTL : 2.30 (+2.22%)
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

AUTL : 2.30 (+2.22%)
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

AUTL : 2.30 (+2.22%)
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations

AUTL : 2.30 (+2.22%)
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

AUTL : 2.30 (+2.22%)
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress

AUTL : 2.30 (+2.22%)
Chart of the Day: Autolus Therapeutics - Effective Cancer Treatments

The Chart of the Day belongs to the oncology based biomedical company Autolus Therapeutics (AUTL) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical...

AUTL : 2.30 (+2.22%)

Business Summary

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London,...

See More

Key Turning Points

3rd Resistance Point 2.47
2nd Resistance Point 2.40
1st Resistance Point 2.35
Last Price 2.30
1st Support Level 2.23
2nd Support Level 2.16
3rd Support Level 2.11

See More

52-Week High 7.45
Fibonacci 61.8% 5.39
Fibonacci 50% 4.76
Fibonacci 38.2% 4.13
Last Price 2.30
52-Week Low 2.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar